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7RESEARCH Open AccessIMRT with 18FDG-PET\CT based simultaneous
integrated boost for treatment of nodal positive
cervical cancer
Nikola Cihoric1, Coya Tapia3, Kamilla Krüger1, Daniel M Aebersold1, Bernd Klaeser2 and Kristina Lössl1*Abstract
Background: To evaluate toxicity and outcome of intensity modulated radiotherapy (IMRT) with simultaneous
integrated boost (SIB) to the positive lymph nodes in patients with loco-regional advanced cervical cancer (LRACC).
Methods: The study population comprised ten patients with 18FDG-PET\CT positive lymph nodes (LNs), who
underwent chemoradiation with IMRT and SIB. A dose of 50.4 Gy, in daily fractions of 1.8 Gy, was delivered to
primary tumor and draining LNs. Primary tumor received an additional external beam boost to a total dose of
55.8 Gy. A SIB of 62 Gy, in daily fractions of 2 Gy, was delivered to the 18FDG-PET\CT positive LNs. Finally, a high
dose rate brachytherapy (HDRB) boost (15 – 18 Gy) was administered to the primary tumor. The primary goal of
this study was to evaluate acute and early late toxicity and loco-regional control.
Results: The median number of irradiated LNs per patient was 3 (range: 1–6) with a median middle nodal
SIB-volume of 26.10 cm3 (range, 11.9-82.50 cm3). Median follow-up was 20 months (range, 12 to 30 months). Acute
and late grade 3 toxicity was observed in 1 patient. Three of the patients developed a recurrence, one in the form
of a local tumor relapse, one had a paraaortic LN metastasis outside the treated volume and the last one developed
a distant metastasis.
Conclusion: IMRT with SIB in the region of 18FDG-PET positive lymph nodes appears to be an effective therapy
with acceptable toxicity and might be useful in the treatment of patients with locally advanced cervical cancer.
Keywords: Cervical cancer, Loco-regional lymph nodes, Intensity modulated radiotherapy, Simultaneous
integrated boostBackground
Despite advances in radiotherapy and combined treatment
modalities, overall and disease free survival in LRACC re-
main unsatisfactory. A third of patients will develop recur-
rence within 2 years following therapy and 5-year relative
survival for patients with affected regional LN is 57% [1-3].
In the absence of systemic metastasis, the most important
predictive factor is the loco-regional LN status [4-6].
These facts lead to the hypothesis that effective treat-
ment of loco-regional disease results in better disease
control and longer survival. Additionally, effective loco-
regional control may also prevent later complications* Correspondence: kristina.loessl@insel.ch
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unless otherwise stated.caused by pelvic tumor growth. The primary tumor is
treated with combination of a external beam radiother-
apy (EBRT) and brachytherapy boost with doses that
usually exceed 70 Gy (biological effective dose BED).
Such dose levels are generally considered to be sufficient
for local disease control and can be safely delivered due
to the excellent conformity of brachytherapy. Due to
the high level of toxicity, conventional EBRT technique
(3-4-field-box) fails to deliver the necessary dose to
treat gross disease in loco-regional LNs. A dose recom-
mendation for treatment of clinically visible tumor
manifestation in LNs is not well defined and varies be-
tween 55 and 60 Gy [7,8]. Higher conformity of IMRT
helps to limit the dose to pelvic and abdominal organs
at risk and results in a lower incidence of early and late
toxicity [9]. Besides improving the therapeutic ratio,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.ro-journal.com/content/9/1/83IMRT is capable of delivering different doses to different
parts of the irradiated volume through dose painting or a
simultaneous integrated boost (SIB) – a concept which
has been studied in different tumor entities. Several au-
thors have evaluated the use of SIB in the treatment of
cervical cancer in preoperative settings and dose escal-
ation in the parametric region [10-14].
Due to the many advantages of IMRT, we have devel-
oped a protocol addressing the treatment of 18FDG-PET
\CT positive LNs using a SIB technique. The main goals
of this study were to evaluate toxicity and effectiveness
of the proposed therapy concept.
Methods
Patients
Patients with 18FDG-PET\CT positive pelvic or para-
aortic LN were selected for treatment with radiotherapy
delivered by SIB IMRT, according to our institutional
standard protocol developed in 2009. Before therapy, all
patients underwent a complete staging workup including
medical history, physical and gynecologic examination,
tumor biopsy, cystoscopy, manual rectal examination
and anoscopy, magnetic resonance (MRI) and whole
body 18FDG-PET\CT scan. Tumor staging was defined
according to the International Federation of Obstetrics
and Gynecology (FIGO) and TNM-UICC system. In the
period between 03/2009 and 10/2010, ten patients were
treated by IMRT SIB dose escalation to the region where
18FDG-PET\CT positive LNs were identified. No add-
itional metastatic lymph nodes were detected on pelvic
MRI. The median age at time of therapy was 53 years
(range 42 to 83 years). Eight patients received concomi-
tant weekly cisplatin chemotherapy (40 mg/m2). Two
patients did not receive chemotherapy due to contrain-
dications. Patient characteristics are summarized in
Table 1. This study was approved by the local ethics
committee (Kantonale Ethikkommission Bern).Table 1 Patient characteristic
Patient # Age, years FIGO stage Histology (squ
cell carcinom
adenocarcinom
1 63 IVA SCC
2 42 IIIB SCC
3 42 IIIB SCC
4 56 IIB SCC
5 51 IIB SCC
6 42 IIIB SCC
7 71 IIIB SCC
8 51 IIIB AC
9 74 IIB SCC
10 83 IIB SCCRadiotherapy
A planning computed tomography (CT) scan was per-
formed in supine position without contrast with slice
thickness of 3 mm. Patients were instructed to come for
the CT and radiotherapy with a full bladder. Image sets
acquired by CT, diagnostic 18FDG-PET\CT and MRI
were imported into the Eclipse Planning System (Varian
Medical System, Paolo Alto, CA). We used “automatic
matching algorithm”, with manual correction as needed.
Registration quality was considered acceptable if disloca-
tion of bony structures did not exceed 1 mm. The exter-
nal beam radiotherapy was delivered using a dynamic
multi-leaf linear accelerator with photon energies of 6
and 15 MV.
Two patients were treated with para-aortic RT. Eight
patients were treated with a sequential IMRT boost in
the primary tumor region with a median dose of 5.4 Gy
(range 5.0 to 21.4 Gy). In one patient the external beam
radiotherapy dose to the primary tumor was escalated to
the total dose of 72 Gy because brachytherapy was not
possible. Brachytherapy was not possible due to the ob-
literation of the cervical canal. The patient refused any
surgical intervention including brachytherapy with nee-
dle insertion.
Target volume delineation
Tumor PTV
The gross tumor volume of the cervix (GTVc) was de-
fined as the visible macroscopic tumor based on all
available clinical and imaging data. Clinical target vol-
ume for primary tumor area (CTVc) encompassed
GTVc, uterus, parametria and upper third of vagina. In
case of vaginal involvement CTVc expanded 2 cm into
the vagina caudal of the tumor. The planning target vol-
ume of primary tumor (PTVc) was created using aniso-
tropic expansion, considering cervical and surrounding
structure movements. The PTVc was expanded toamous
a = SCC;
a = AC)
Tumor grade Weekly concurrent cisplatine
chemotherapy = +; without
chemotherapy = −
3 +
2 +
2 +
2 +
3 +
2 -
3 +
1 +
2 +
2 -
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http://www.ro-journal.com/content/9/1/8315 mm in the antero-dorsal direction and 10 mm in
the lateral direction. Asymmetrical margin for PTV
was based on the fact that that the cervical cancer
movements are not uniform in all directions, as
showed in the work of Beadle et al. [15]. In the dorsal
direction PTVc margin extended maximally to the
posterior rectal wall and in frontal direction max-
imally 2 cm into the bladder.Nodal PTV and SIB volume
The elective clinical target LN volume encompassed the
vasa illiaca externa, interna and communis lymphatic
chain to the aorta bifurcation and presacral LN area. In
case of LN involvement at the level of a. communis or
aortal LN, we extended the elective nodal volume to the
level of renal arteries. A safety margin of 7 mm was
added to construct the planning target volume (PTVn).
PTVc and PTVn were merged to one single planning
target volume (PTVsum).
Nodal gross tumor volume (GTVn) was based on the
data acquired by 18FDG-PET\CT after assessments of
other imaging modalities. Positive LNs were delineated
separately as nodal gross tumor volume (GTVn). PTVsib
was formed by adding a safety margin of 5 mm to the
GTVn.
The prescription dose for PTVsum was 50.4 Gy deliv-
ered in 28 single fractions of 1.8 Gy. Upon completion
of the first phase, three additional fractions were added
to PTVc + PTVsib as external beam boost to a total dose
of 55.8 Gy. Parallel to first and second phase PTVsib
was irradiated with a dose escalation of 31 fractions of
2 Gy to a total dose of 62 Gy.
The example of treatment plan with a metastatic iliacal
LN treated by SIB is shown on Figure 1.Figure 1 Example of a patient treatment plan with a metastatic iliac LConstraints for organs at risk
Organs at risk were delineated on all axial slices. We de-
lineated the rectum up to the sigmoid. The bowel was
contoured to the level extending one vertebral body be-
yond the upper border of the PTV, including large and
small intestines. The bladder and femoral heads were
also contoured. Dose constraints for organs at risk were
standardized as follows: 60% of rectal volume should re-
ceive no more than 50 Gy, 35% of bowel volume should
receive no more than 35Gy, 50% of bladder volume
should receive no more than 50 Gy and 10% of femoral
heads volume should receive no more than 50 Gy.Brachytherapy
EBRT was followed by HDRB boost to the primary
tumor, one week after completion of EBRT. Brachyther-
apy consisted of a total dose from 15 to 18 Gy delivered
in 3 fractions with a single weekly fraction of 5 or 6 Gy,
depending of the previous external beam total dose. We
used a microSelectron® HDRB Unit and a Vienna Ring
CT-MRI Applicator Set. Planning volume for HDRB was
defined on the planning CT with applicators in treat-
ment position. During planning we took into consider-
ation data from an MRI scan performed during the last
week of the EBRT treatment. Treatment volumes were
delineated based on the Gynecological GEC-ESTRO
Working Group recommendations [16].Toxicities
Acute and late toxicities were assessed according to the
Common Terminology Criteria for Adverse Events Ver-
sion 3.0 (CTCAE V3.0) scale. We defined acute toxicity
as occurring during treatment or within the first
3 months after treatment end, whereas late toxicity wasN.
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after treatment. Acute toxicities were evaluated weekly
during the treatment, at 6 weeks and 3 months after
treatment completion. Late toxicities were evaluated
6 months after treatment and thereafter once a year. Eval-
uations of toxicities were done by a radiation oncologist.Follow-up
The initial tumor response was evaluated by a gyneco-
logic oncologist 3 months after radiotherapy and every
3 months thereafter. We conducted a 18FDG-PET\CT
6 months after therapy for evaluation. Failure was de-
fined as persistent disease or recurrence of disease fol-
lowing radiotherapy at any site. The date of failure was
defined as the date of any sign of disease, either clinical
or by imaging. The site of failure was recorded as local,
nodal and distant. Furthermore, a distinction was estab-
lished between in-field nodal failures or “out of field”
nodal failures.
Patients without an event were censored at the date of
last follow-up. Overall survival (OS) was calculated as time
between the first day of radiotherapy to the date of death
from any cause or last date of follow-up. Progression-free
survival (PFS) was calculated as time between the first day
of radiotherapy to the date of any sign of tumor relapse.
Survival was analyzed using Kaplan-Meier plots. All ana-
lyses were carried out using SPSS V 20.0.Results
A detailed overview of LN numbers, corresponding to
SIB volumes and dose coverage for every patient is
shown in Table 2. Dose volume histogram for rectum,
bladder and intestine exposure (median of all 10 pa-
tients) is shown on Figure 2. Median follow-up time for
all patients, excluding one who died three months after
therapy, was 20 months (range 12 to 30 months). TheTable 2 Lymph nodes and corresponding radiotherapy volum
Patient # Total number
of 18FDG PET-CT
positive LNs
External and
internal iliac LN
Common
iliac LN
Para-aort
1 3 1 0 2
2 1 1 0 0
3 2 2 0 0
4 3 3 0 0
5 3 2 1 0
6 6 1 2 3
7 3 2 0 1
8 2 2 0 0
9 1 1 0 0
10 2 2 0 0overall-survival and disease-free survival curves are
shown in Figure 3.
Within the follow-up 7 patients remained diseases free.
Two patients developed disease recurrence and one pa-
tient developed tumor persistence: One patient developed
retroperitoneal LN metastases out of field 6 months after
completion of RT. Twenty two months after completion
of RT the same patient was diagnosed with local in-field
recurrence in region of primary tumor (GTVc). One pa-
tient had tumor persistence diagnosed by 18FDG-PET\CT
five months after RT. One patient developed systemic pro-
gression and para-aortic LN metastases out of field within
one month after completion of radiotherapy.
Treatment related toxicities
Eight patients had some form of unwanted therapy asso-
ciated side effects resulting in minimal discomfort (grade
1 or 2 toxicity). One patient developed acute grade 3
toxicity in the form of cystitis which resulted in severe
dysuria, polyuria and macroscopic hematuria. This pa-
tient was treated with conservative treatment and the
symptoms resolved shortly after the therapy. An import-
ant confounding factor for this patient was an initially
diagnosed urinary incontinence, rendering the patient
incapable to maintain a full bladder during radiotherapy.
The patient refused any form of catheterization. There-
fore, the bladder filling could not be controlled during
the radiotherapy. Dosimetric parameters for this patient
were as follows: V30 = 99.7, V40 = 85.5, V50 = 14.0,
V60 = 0.0; DMAX = 51.8 Gy. Overview of acute toxic-
ities is presented in Table 3. One patient develop
chronic vaginal dryness grade 3. We did not record
any other late serious adverse event.
Discussion
Presence of LN metastases in cervical cancer patients is
a significant risk factor for disease recurrence. It hases with dose coverage
ic LN SIB volumes (cm3) Mean
dose (Gy)
Min. dose (Gy) Max.
dose (Gy)
71.30 60.03 53.19 63.06
29.50 62.14 59.60 63.20
14.60 61.16 58.10 61.81
17.20 61.97 59.49 62.80
22.70 60.96 58.79 61.81
82.50 63.67 54.20 66.87
18.40 61.40 58.66 62.74
33.60 61.22 59.20 62.31
11.90 60.92 57.48 62.92
33.50 61.20 57.84 62.89
Figure 2 Dose Volume Histogram - median values for rectum, bladder and intestine volumes.
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with relapsed disease have a component of nodal failure.
The reason for those unsatisfactory results could be at-
tributed to insufficient dose delivered to the nodal re-
gion especially in the case of clinically suspected nodal
metastasis, geographical miss or combination of both
factors [7,17]. By reviewing currently available data,
18FDG-PET\CT shows more favorable results in the de-
tection of regional disease when compared to the CT or
MRI [4,18]. In addition, there is emerging evidence that
the incorporation of modern molecular imaging (PET-
CT) into the diagnosis and treatment contributes to better
disease control [17]. This contribution can be reflected in
better diagnosis of local and regional disease spread with
consequent better delineation based on molecular data as
shown in the work from Kidd et al. [17].
In an attempt to improve the therapeutic approach to
nodal positive cervical cancer, we focused on a feasibility
study of chemoradiation with IMRT and SIB to 18FDG-
PET\CT positive LNs. One possible advantage in adoptingFigure 3 Kaplan-Meier curves representing disease free survival and oIMRT relates to treatment planning with SIB based on
data acquired from a 18FDG-PET\CT. With our treat-
ment concept we have tried to avoid the aforementioned
pitfalls with the incorporation of molecular data in the
planning, and by delivering sufficient dose to the LN me-
tastases. Moreover incorporation of SIB may shorten over-
all treatment time and can contribute to the disease
control [19]. The data regarding this therapeutic approach
is, however, limited. Marnitz S et al. described utilization
of SIB delivered with tomotherapy in 40 patients with cer-
vical cancer, focussing on use of the SIB for local cervical
gross tumor. They treated the parametric region with SIB
(single dose 2.12 Gy) to the 59.36 Gy. The region of inter-
est was previously marked by surgical titan clips place-
ment. The treatment results were satisfactory without
excess in toxicity. Vandecasteele K. et al. (2009) report re-
sults of SIB implementation with intensity modulated arc
therapy [10]. They created treatment plans for 4 patients
with 18 FDG PET-CT positive lymph nodes. SIB volumes
for nodes and primary treatment volume were delineatedverall survival.
Table 3 Acute toxicity according to CTCAE V3.0
Patient # Upper
gastrointestinal
Lower
gastrointestinal
Urinary Genital Skin
1 1 0 0 0 0
2 0 0 1 1 1
3 2 0 0 1 0
4 2 0 0 2 0
5 2 1 3 0 0
6 1 0 0 1 0
7 0 0 0 0 0
8 1 0 0 0 0
9 0 0 0 0 0
10 0 1 1 0 0
Gr 0 4 8 7 6 9
Gr 1 3 2 2 3 1
Gr 2 3 0 0 1 0
Gr 3 0 0 1 0 0
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nodes was 60 Gy [10-14,20]. Compared to these published
results, we applied sligthly higher total doses to 18 FDG
PET-CT positive lymph nodes: We delivered 62 Gy, while
remaining volume constraints for organs at risk.
The main concern when using dose escalation is the
elevated number of acute serious adverse events. Several
dosimetric studies have evaluated advantages of IMRT
for cervical cancer in terms of dose reduction delivered
to the organs at risk. Portelance et al. showed a 30 to
70% reduction in dose to the organs at risk with IMRT
in comparison with conventional EBRT [21]. Roeske
et al. achieved good target coverage with reduced intes-
tinal dose [22]. Chan et al. and Kavanagh et al. demon-
strated better protection of small bowel, rectum and
bladder with IMRT over 4-Field and 3D conformal
EBRT [23,24].
Current clinical experience to lymph nodes in cervical
cancer is mainly based on dose regimes up to 50 Gy.
Further dose escalation with conventional technique or
even with 3D conformal therapy would put the bowel at
risk. In case of SIB in pelvic and para-aortic regions, the
risk of acute bowel injury could be an issue of concern.
To date, there are generally no widely accepted dose
constraints for organs and tissues and several proposals
have been published by other authors. Gerszten K. et al.
utilized a more aggressive approach in treatment of cer-
vical cancer with extended field radiotherapy and added
a 55 Gy boost to involved nodes. Authors proposed dose
constraints as follows: Maximal dose for rectum, bladder
and intestine should be ≤ 54 Gy. 40% of rectal volume
and 50% of bladder volume should not receive more
than 40Gy. Maximum of 35% intestinal volume shouldnot receive more than 35 Gy [25]. Esthappan et al.
treated PET positive para-aortic LNs with 60 Gy and
elective nodal volume with 50 Gy. The DVH analysis
showed that treatment plans irradiate approximately
50% of bowel with 25 Gy, less than 10% of bowel with
50 Gy and less than 1% received 60 Gy [26]. Although
we have higher constraints for bladder and rectum we
did not record higher incidence of toxicities compared
with literature. Our dose constraints were easily achiev-
able in most cases (Figure 2).
The 2 year disease free survival in our group (Figure 3.)
is comparable with results from other authors. In the
study from Hasselle et al. two year disease free survival
(DFS) for patients with IIB-IVA cervical cancer treated
with IMRT was reported as of nearly 70%. In the same
study cumulative incidence of isolated pelvic failure (PF)
and combined PF and distant failure was 8.6% and 10.1%,
respectively [9]. Sushil B. et al. report a 51% 2 year DFS in
patients treated with extended field IMRT in similar
patients group [27]. In sequential paper Vandecasteele K.
et al. (2012) report results of SIB utilization, with the
same technique [10], in neoadjuvant settings in 30 pa-
tients [20]. Eleven patients had positive lymph nodes.
Lymph nodes < 2 cm in diameter had 100% complete
pathological response in contrast with lymph nodes ≥ 2 cm
where complete response was achieved in 50% cases. In our
cohort we achieved regional control of 100% within median
follow up of 20 months. We do not conduct a surgical
staging due to the fact that the morbidity rate following
treatment is higher in patients receiving a combination
of surgery and RT. Landoni et al. showed in a randomized
trial that a subgroup of patients treated with postoperative
RT had similar survival but a higher incidence of treat-
ment related toxicities [28,29]. Data related to the laparo-
scopic staging and treatment of patients with cervical
cancer is limited. Even though literature suggests different
approaches this is still an open question. The available evi-
dence for laparoscopic staging and treatment are mainly
based on retrospective studies. One randomized trial
showed no benefit of surgical vs. clinical approach in the
staging and treatment of patients with cervical cancer [30].
The latest Cochrane Review found no evidence that pre-
treatment surgical para-aortic lymph node assessment
for locally advanced cervical cancer is beneficial. How-
ever, they stated that the surgical approach could poten-
tially have an adverse effect on survival [31]. A potential
benefit of the laparoscopic staging is seen in low-stage
cervix cancer (< FIGO IB2). The sensitivity of the lap-
aroscopic staging is higher compared to staging with
PET-CT [32]. In addition an NCI consensus recommends
that a combination of surgery followed by radiotherapy
should be avoided.
Late toxicities of the proposed treatment concept are
an important issue. Gastrointestinal toxicities occur in
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http://www.ro-journal.com/content/9/1/83ca. 10% of all patients and most occur within the first
two years. The urological toxicities can rise up to 10%
but their incidence can increase during time. New late
toxicities can be detected up to 20 years after treatment.
Our median follow-up of 20 months is limited in the de-
tection of potential late toxicities [33].
Although being limited due to its small size and retro-
spective nature, the present study contributes to the no-
tion that the application of a high dose of radiation in
the region of 18FDG-PET\CT positive LNs by means of
IMRT and SIB is feasible, with an acceptable profile of
unwanted events and good loco-regional control, com-
parable with other published studies.
However, a prospective investigation with a larger
sample size is needed to definitely confirm safety and ef-
ficiency of this therapeutic approach.
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